David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.
Clinical Pearls
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.
This was a phase I study looking at MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
MEDI3617 is a selective angiopoietin-2 inhibitor and functions much like bevacizumab.
Several responses were seen in ovarian cancer when MEDI3617 was administered alone. At the highest dosage of MEDI3617, some patients experienced severe swelling that persisted after treatment was stopped.
Responses were also seen across other tumor types when MEDI3617 was used in combination with chemotherapies and bevacizumab.
